Aims: Electronic health records (EHRs) are widely used in medication adherence (MA) assessment. Poor adherence in patients with inflammatory bowel diseases (IBD) can lead to worse disease outcomes and increased health costs. This study explores the suitability of southern New Zealand EHRs for estimating adherence, and the relationship between adherence and corticosteroid dispensings (indicating negative disease outcomes).
Methods: Medication dispensing EHR data of former Southern District Health Board IBD patients were analysed to estimate 3-year adherence, using daily polypharmacy possession ratio. The correlation with the number of corticosteroid dispensings was investigated.
Results: Of 248/1,290 (19%) consenting patients, only 108/248 (44%) had sufficient data available (46%/54% Crohn's disease/ulcerative colitis; 57% female; 89.8%/0.9% NZ European/Māori; mean 5.1 corticosteroid dispensings). Mean adherence was 83.2% (95% confidence interval [CI] 80.0-86.4; standard deviation [SD]:16.7), with 69% of patients having MA ≥80% (good adherence). Median adherence was 13% higher for males versus females (96% vs 83%; p=0.0001). There was no correlation between adherence and the number of corticosteroid dispensings (Pearson's r=0.11; p>0.05). These findings should be considered with caution as the data were not obtained from all pharmacies and the quantum/nature of missing data is unknown.
Conclusions: The patients' adherence seems high, with no correlation with corticosteroid dispensings demonstrated. Useful EHR data are available but need optimisation for adherence assessments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.26635/6965.6209 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Environmental impact of inhaler therapies in a cystic fibrosis unit: Strategies for sustainability.
Farm Hosp
December 2024
Servicio de Farmacia, Hospital Universitario Vall'Hebron, Barcelona, España.
Objective: Inhaled therapy is essential in cystic fibrosis; however, inhalers have a significant environmental impact due to the greenhouse gases (GHGs) emitted. The environmental impact of a product is estimated by its carbon footprint (CF). Pressurized metered-dose inhalers (pMDIs) have a higher CF than dry powder inhalers (DPIs) and soft mist inhalers (SMIs) due to the incorporation of GHGs.
View Article and Find Full Text PDFReal-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States.
Ann Allergy Asthma Immunol
November 2024
Value Evidence and Outcomes, GSK, Upper Providence, Pennsylvania. Electronic address:
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, chronic inflammatory disease characterized by asthma and small/medium vessel vasculitis. Mepolizumab is approved for use in EGPA disease management alongside oral corticosteroids (OCS), but evidence of its real-world impact is limited.
Objective: To compare real-world treatment patterns and health outcomes, particularly OCS use, EGPA-related hospitalizations/relapses, and asthma exacerbations pre- and post-mepolizumab initiation in US patients with EGPA.
Development and Validation of Claims-Based Algorithms for Conjunctivitis and Keratitis.
Pharmacoepidemiol Drug Saf
November 2024
Optum Epidemiology, Boston, Massachusetts, USA.
Background: Ocular surface disorders have been reported among patients with various medical conditions, including atopic dermatitis (AD). Nonetheless, validated algorithms to identify conjunctivitis and keratitis in claims data are lacking.
Objective: Develop validated, claims-based algorithms for conjunctivitis and keratitis among patients with AD using medical records.
Incidence of serious respiratory tract infections and associated characteristics in a population exposed to immunosuppressive therapies: a register-based population study.
BMC Infect Dis
October 2024
Service de Médecine Interne, APHP, Hôpital Ambroise Paré, Université de Versailles Saint-Quentin-en-Yvelines, 9 Av. Charles de Gaulle, Boulogne-Billancourt, 92100, France.
Article Synopsis
- The study investigates the incidence of serious respiratory tract infections (SRI) among individuals receiving immunosuppressive therapies, using data from French healthcare between 2014-2019.
- A total of 24,122 patients were analyzed, revealing a standardized SRI incidence rate of 1,398 per 100,000 person-years, with significant associations found between SRI and various chronic conditions like cancer, respiratory diseases, and diabetes.
- It concludes that a history of chronic diseases increases the risk of SRI in patients on immunosuppressive therapies, and that this risk is lower in those treated with conventional synthetic disease-modifying anti-rheumatic drugs compared to corticosteroids.
Intranasal corticosteroid users in The Netherlands: A drug utilization study.
J Allergy Clin Immunol Glob
November 2024
Department of Paediatrics, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Background: To improve (patient-tailored) instructions for intranasal corticosteroid (INC) administration, we need to gain insight into specific characteristics of INC users and comedication use.
Objective: We examined INC prescriptions obtained from the Dutch InterAction Database to gain insight into the prevalence and incidence rates, INC use in previous years, and comedication.
Methods: We retrospectively examined INC prescriptions written between January 1, 2015, and December 31, 2019.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!